Back

Cardioprotection beyond the guidelines: the SAFE trial results

27 August 2023 (11:40 - 11:50)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity of cancer therapies Cardiotoxicity of Drugs and Other Therapies ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Giuseppe Barletta

Careggi University Hospital (AOUC), Florence (Italy)

5 More presentations in this session

Presentation thumbnail
Mitochondrial dynamics and myocardial metabolism alterations during anthracycline-cardiotoxicity
Miss A. Diaz-Guerra Priego (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Adult survivors of childhood cancer have significant levels of impaired cardiorespiratory fitness, inflammatory markers and poor quality of life outcomes
Doctor C. McCune (Belfast, GB)
Abstract Slides Video
Presentation thumbnail
Establishment of an in vivo murine model of immune checkPoint inhibitors cardiotoxicity: emerging role of vascular permeability in pembrolizumab-induced cardiotoxicity.
Doctor P. Efentakis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Association between vitamin D receptor gene polymorphism and cardiomyopathy in response to adriamycin treatment among breast cancer patients
Miss R. Mokhtar (Cairo, EG)
Abstract Slides Video
Presentation thumbnail
Association between immune checkpoint inhibitors and heart failure hospitalizations: a population-based self-controlled case series
Professor G. Tse (Hong Kong, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity of cancer therapies
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 11:40 CET
You may be interested in
thumbnail
Congress Presentation
The right ventricle is not spared by the cardiotoxic effects of chemotherapy for breast cancer. Results of SAFE trial.
26 August 2023
thumbnail
Congress Presentation
Breast cancer and cardiotoxicity: an update
30 August 2024
thumbnail
Congress Session
Preventing cardiotoxicity
19 June 2026
thumbnail
Congress Presentation
Use of emgliflozin in the prevention of cardotoxicity.The EMPACARD - PILOT TRIAL. 12 - months Follow -up
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources